ARVN
Price
$7.53
Change
+$0.61 (+8.82%)
Updated
Jun 6 closing price
Capitalization
505.1M
53 days until earnings call
ERAS
Price
$1.60
Change
+$0.03 (+1.91%)
Updated
Jun 6 closing price
Capitalization
444.76M
60 days until earnings call
Interact to see
Advertisement

ARVN vs ERAS

Header iconARVN vs ERAS Comparison
Open Charts ARVN vs ERASBanner chart's image
Arvinas
Price$7.53
Change+$0.61 (+8.82%)
Volume$2.76M
Capitalization505.1M
Erasca
Price$1.60
Change+$0.03 (+1.91%)
Volume$1.73M
Capitalization444.76M
ARVN vs ERAS Comparison Chart
Loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARVN vs. ERAS commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (ARVN: $7.28 vs. ERAS: $1.10)
Brand notoriety: ARVN and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 139% vs. ERAS: 88%
Market capitalization -- ARVN: $505.1M vs. ERAS: $444.76M
ARVN [@Biotechnology] is valued at $505.1M. ERAS’s [@Biotechnology] market capitalization is $444.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARVN and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 3 bearish.
  • ERAS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ARVN is a better buy in the short-term than ERAS.

Price Growth

ARVN (@Biotechnology) experienced а +16.56% price change this week, while ERAS (@Biotechnology) price change was -9.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ARVN is expected to report earnings on Jul 31, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARVN($505M) has a higher market cap than ERAS($445M). ERAS YTD gains are higher at: -56.175 vs. ARVN (-61.998). ERAS has higher annual earnings (EBITDA): -153.28M vs. ARVN (-243.6M). ARVN has more cash in the bank: 1.04B vs. ERAS (298M). ARVN has less debt than ERAS: ARVN (9.7M) vs ERAS (51.9M). ARVN has higher revenues than ERAS: ARVN (263M) vs ERAS (0).
ARVNERASARVN / ERAS
Capitalization505M445M113%
EBITDA-243.6M-153.28M159%
Gain YTD-61.998-56.175110%
P/E RatioN/AN/A-
Revenue263M0-
Total Cash1.04B298M349%
Total Debt9.7M51.9M19%
FUNDAMENTALS RATINGS
ARVN: Fundamental Ratings
ARVN
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARVNERAS
RSI
ODDS (%)
Bullish Trend 12 days ago
89%
Bullish Trend 12 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
89%
Bullish Trend 12 days ago
87%
Momentum
ODDS (%)
Bullish Trend 12 days ago
81%
Bearish Trend 12 days ago
90%
MACD
ODDS (%)
Bullish Trend 12 days ago
79%
Bearish Trend 12 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
77%
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
86%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend about 1 month ago
79%
Declines
ODDS (%)
Bearish Trend 26 days ago
82%
Bearish Trend 18 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
86%
Bullish Trend 12 days ago
86%
Aroon
ODDS (%)
Bullish Trend 12 days ago
62%
Bullish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with ATXS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+8.89%
ATXS - ARVN
39%
Loosely correlated
+6.85%
ERAS - ARVN
39%
Loosely correlated
+1.85%
ABOS - ARVN
38%
Loosely correlated
N/A
TECH - ARVN
37%
Loosely correlated
-1.56%
CRBU - ARVN
37%
Loosely correlated
+2.75%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.85%
RVMD - ERAS
57%
Loosely correlated
+2.04%
XNCR - ERAS
57%
Loosely correlated
-2.58%
KYMR - ERAS
56%
Loosely correlated
+2.35%
BEAM - ERAS
53%
Loosely correlated
-0.88%
APGE - ERAS
53%
Loosely correlated
-1.30%
More